Acquisition momentum Harmony Biosciences acquired Epygenix for 35M, signaling a potential for continued collaboration or integration opportunities with a larger CNS-focused portfolio and a need to align ongoing or future trials with acquirer priorities.

Phase 3 focus Second phase 3 trial in Lennox-Gastaut syndrome indicates a late-stage development trajectory and potential near-term appealing assets for partners seeking late-stage epilepsy candidates.

Rare epilepsy niche Specialization in Dravet syndrome and other genetic epilepsies positions the company as a target for partnerships, licensing, or co-development with firms seeking to bolster rare disease CNS pipelines.

Small-team agility Low headcount suggests streamlined operations and potential needs for strategic partnerships, contract research, or outsourcing to accelerate trials, manufacturing, and regulatory activities.

Financial footing Revenue under one million and recent acquisition imply access to or interest in collaborations, equity investments, milestone-based deals, or licensing arrangements to de-risk and scale their clinical programs.